Sepsiste Statinlerin Rolü

Göncüoğlu, Cansu; Demirkan, Kutay; Unal, Serhat; Çetinadam, Hafsa Nur

doi:10.5578/flora.20219704

Sepsiste Statinlerin Rolü

Cansu GÖNCÜOĞLU, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Klinik Eczacılık Anabilim Dalı, Ankara, Türkiye)

Hafsa Nur ÇETİNADAM, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Klinik Eczacılık Anabilim Dalı, Ankara, Türkiye)

Kutay DEMİRKAN, (Hacettepe Üniversitesi, Eczacılık Fakültesi, Klinik Eczacılık Anabilim Dalı, Ankara, Türkiye)

Serhat ÜNAL (Hacettepe Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara, Türkiye)

Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi

5 0

Yıl: 2021 Cilt: 26 Sayı: 3 Sayfa Aralığı: 369 - 377 Metin Dili: Türkçe DOI: 10.5578/flora.20219704 İndeks Tarihi: 31-12-2021

Sepsiste Statinlerin Rolü

Öz:

Sepsis, bakteri, virüs, parazit veya fungal mikroorganizmaların neden olduğu infeksiyona karşı düzensiz konak yanıtına bağlı organ disfonksiyonu olarak tanımlanmakta, morbidite veya mortaliteye neden olabilmektedir. Statinlerin ateroskleroz ve çeşitli kardiyovasküler hastalıklardaki yararı, yüksek kolesterol düzeylerini düşürerek endotelde yaptığı olumlu etkiyle açıklanmaktadır. Statinlerin lipit düşürücü etkilerine ek olarak antiinflamatuvar, antitrombotik, antioksidan etki gibi pleiotropik etkileri de bulunmaktadır. Statinlerle yapılan ön tedavinin sepsiste sağkalımı etkileyebileceği gösterilmiştir. Sepsis ve septik şokta inflamatuvar mediyatörlere maruz kalan endotel hücrelerinden sitokin salınımı, prokoagülan moleküller, trombosit üretimi teşvik edilmektedir. Ayrıca sepsiste inflamasyon gelişmesiyle nötrofil, fagosit artışı nedeniyle enfekte olan dokuda damar permeabilitesi artmakta ve doku hasarı meydana gelmektedir. Sonuçta vasküler tonusu düzenleyen homeostaz bozulmakta ve endotel hasarı meydana gelmektedir. Statinler endotelde vasküler gevşemeyi sağlayarak, adezyon molekülleri ve sitokinlerin ekspresyonunu azaltarak sepsise etki etmektedir. Güncel bilgiler ışığında, sepsis tedavisinde, pleiotropik etkilerinden yararlanmak için statin kullanımının önerilebilmesi için daha kapsamlı ve daha fazla sayıda çalışmaya ihtiyaç duyulmaktadır.

Anahtar Kelime:

The Role of Statins in Sepsis

Öz:

Sepsis is defined as organ dysfunction due to an irregular host response to infection caused by bacteria, viruses, parasites or fungal microorganisms and may cause morbidity or mortality. The benefit of statins in atherosclerosis and various cardiovascular diseases is explained by their positive effect on the endothelium by lowering high cholesterol levels. Statins have pleiotropic effects such as anti-inflammatory, antithrombotic and antioxidant effects in addition to their lipid lowering effects. It has been shown that pretreatment with statins may affect survival in sepsis. In sepsis and septic shock, cytokine release from endothelial cells, procoagulant molecules and thrombocyte production are encouraged. In addition, with the development of inflammation in sepsis, vascular permeability increases in the infected tissue due to the increase of neutrophils and phagocytes and tissue damage occurs. Thus, homeostasis regulating vascular tone is disturbed and endothelial damage is formed. Statins act on sepsis by providing vascular relaxation in the endothelium and reducing the expression of adhesion molecules and cytokines. In the light of current knowledge, more comprehensive studies are needed to recommend the use of statins to benefit from its pleiotropic effects in the treatment of sepsis.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Barrier KM. Summary of the 2016 international surviving sepsis campaign: A clinician’s guide. Critical care nursing clinics of North America 2018;30(3):311-21.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. The New England J Med 2003;348(16):1546-54.
3. TATD Kritik Bakım Çalışma Grubu. Sepsis tanı ve tedavi kılavuzu 2018 [Available from: https://www.tatd.org.tr/uploads/tbl_calisma_grubu_belgeleri/5bdc0b59545b8_tbl_calisma_grubu_belgeleri2018113121.pdf.
4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 2016;315(8):801-10.
5. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. . Am J Respir Crit Care Med 2016;193(3):259-72.
6. Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Crit Care Med 2018;46(6):997- 1000.
7. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock. Crit Care Med 2017;45(3):486-552.
8. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34(2):344-53.
9. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115(6):457-69.
10. Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg 2012;78(1):1-8.
11. Megyeri K, Au WC, Rosztoczy I, Raj NB, Miller RL, Tomai MA, et al. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 1995;15(4):2207-18.
12. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635-700.
13. Baddeley AD SJ. Sepsis syndrome. In: Wilson WR, Sande, M.A., editor. Current Diagnosis and Treatment In Infectious Diseases. McGraw-Hill, New York2001.
14. Belloni PN, Nicolson GL. Differential expression of cell surface glycoproteins on various organ-derived microvascular endothelia and endothelial cell cultures. J Cell Physiol 1988;136(3):398-410.
15. Heffner JE, Sahn SA, Repine JE. The role of platelets in the adult respiratory distress syndrome. Culprits or bystanders? Am Rev Respir Dis 1987;135(2):482-92.
16. Miyauchi T, Tomobe Y, Shiba R, Ishikawa T, Yanagisawa M, Kimura S, et al. Involvement of endothelin in the regulation of human vascular tonus. Potent vasoconstrictor effect and existence in endothelial cells. Circulation 1990;81(6):1874-80.
17. Gopalakrishna D, Pennington S, Karaa A, Clemens MG. ET-1 Stimulates Superoxide Production by eNOS Following Exposure of Vascular Endothelial Cells to Endotoxin. Shock (Augusta, Ga) 2016;46(1):60-6.
18. Matsuda N, Hayashi Y, Takahashi Y, Hattori Y. Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric arteries from septic rabbits depending on the altered phosphatidylinositol 3-kinase/Akt pathway: reversal effect of fluvastatin therapy. J Pharmacol Exp Therapeutics 2006;319(3):1348-54.
19. Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004;104(13):3958-64.
20. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in sepsis. Scand J Infect Dis 2003;35(9):535-44.
21. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984;63(2):486-9.
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England journal of medicine. 1995;333(20):1301-7.
23. Türkiye Endokrinoloji ve Metabolizma Derneği Obezite LM, Hipertansiyon Çalışma Grubu,. Dislipidemi tanı ve tedavi kılavuzu: Türkiye Endokrinoloji ve Metabolizma Derneği; 2019. Available from:https://temd.org.tr/admin/ uploads/tbl_kilavuz/20190506163838-2019tbl_kilavuz61855bdd04.pdf.
24. Shahbaz SK, Sadeghi M, Penson PE, Sahebkar AJPR. Regulatory T cells: possible mediators for the anti-inflammatory action of statins. 2019:104469.
25. Peters K, Unger RE, Brunner J, Kirkpatrick CJ. Molecular basis of endothelial dysfunction in sepsis. Cardiovascular Res 2003;60(1):49-57.
26. Parker JL, Adams HR. Selective inhibition of endothelium-dependent vasodilator capacity by Escherichia coli endotoxemia. Circ Res. 1993;72(3):539-51.
27. Subramani J, Kathirvel K, Leo MD, Kuntamallappanavar G, Uttam Singh T, Mishra SK. Atorvastatin restores the impaired vascular endothelium-dependent relaxations mediated by nitric oxide and endothelium-derived hyperpolarizing factors but not hypotension in sepsis. J Cardiovascular Pharmacol 2009;54(6):526-34.
28. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. Journal Pharmacol Exp Therapeutics 2000;294(3):1043-6.
29. Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 2006;69(9):1535-42.
30. Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock (Augusta, Ga) 2004;21(3):271-5.
31. Janda S, Young A, FitzGerald JM, Etminan M, Swiston JJJocc. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. 2010;25(4):656. e7-. e22.
32. Fraunberger P, Grone E, Grone HJ, Walli AK. Simvastatin reduces endotoxin-induced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. Shock (Augusta, Ga) 2009;32(2):159-63.
33. Zhang S, Luo L, Wang Y, Rahman M, Lepsenyi M, Syk I, et al. Simvastatin protects against T cell immune dysfunction in abdominal sepsis. Shock (Augusta, Ga). 2012;38(5):524- 31.
34. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, et al. Role of NFkappaB in the mortality of sepsis. J Clin Invest 1997;100(5):972-85.
35. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intens Care Med 2009;35(7):1255-60.
36. Schmidt H, Hennen R, Keller A, Russ M, Muller-Werdan U, Werdan K, et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intens Care Med 2006;32(8):1248-51.
37. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intens Care Med 2006;32(1):75-9.
38. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61(11):957-61.
39. Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007;35(2):372-8.
40. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110(7):880-5.
41. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006;189(2):408-13.
42. Lee CC, Lee MG, Hsu TC, Porta L, Chang SS, Yo CH, et al. A population-based cohort study on the drug-specific effect of statins on sepsis outcome. Chest 2018;153(4):805-15.
43. Kamat SA, Gandhi SK, Davidson M. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opinion 2007;23(5):1121-30.
44. Thickett DR, Armstrong L, Christie SJ, Millar AB. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164(9):1601-5.
45. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997;17(8):1521-6.
46. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97(12):1129-35.
47. Vaughan CJ, Gotto AM Jr., Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35(1):1-10.
48. Gui Q, Yang Y, Zhang J. Effects of statins on the development of sepsis and organ dysfunction in hospitalized older patients in China. The Brazilian journal of infectious diseases: an official publication of the Brazilian Soc Infect Dis 2017;21(3):255-62.
49. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sorensen HT, Schonheyder HC, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34(4):1080-6.
50. Patel JM, Snaith C, Thickett DR, Linhartova L, Melody T, Hawkey P, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012;16(6):R231.
51. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, et al. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 2003;107(2):258-63.
52. Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J 2005;149(3):451-7.
53. Leung S, Pokharel R, Gong MN. Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis. Critic Care Med 2012;40(4):1064-71.
54. Goodin J, Manrique C, Dulohery M, Sampson J, Saettele M, Dabbagh O. Effect of statins on the clinical outcomes of patients with sepsis. Anaesth Intensive Care 2011;39(6):1051-5.
55. Deshpande A, Pasupuleti V, Rothberg MB. Statin therapy and mortality from sepsis: a meta-analysis of randomized trials. Am J Med 2015;128(4):410-7.e1.
56. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Inten Care Med 2006;32(1):160-4.
57. Thomas G, Hraiech S, Loundou A, Truwit J, Kruger P, McAuley DF, et al. Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials. Minerva Anestesiol 2015;81(8):921-30.
58. Pertzov B, Eliakim-Raz N, Atamna H, Trestioreanu AZ, Yahav D, Leibovici L. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - A systematic review and meta-analysis. Clin Microbiol Infect 2019;25(3):280-9.
59. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 2009;29(6):621-30.
60. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420(6917):885-91.

APA	Göncüoğlu C, Çetinadam H, Demirkan K, Unal S (2021). Sepsiste Statinlerin Rolü. , 369 - 377. 10.5578/flora.20219704
Chicago	Göncüoğlu Cansu,Çetinadam Hafsa Nur,Demirkan Kutay,Unal Serhat Sepsiste Statinlerin Rolü. (2021): 369 - 377. 10.5578/flora.20219704
MLA	Göncüoğlu Cansu,Çetinadam Hafsa Nur,Demirkan Kutay,Unal Serhat Sepsiste Statinlerin Rolü. , 2021, ss.369 - 377. 10.5578/flora.20219704
AMA	Göncüoğlu C,Çetinadam H,Demirkan K,Unal S Sepsiste Statinlerin Rolü. . 2021; 369 - 377. 10.5578/flora.20219704
Vancouver	Göncüoğlu C,Çetinadam H,Demirkan K,Unal S Sepsiste Statinlerin Rolü. . 2021; 369 - 377. 10.5578/flora.20219704
IEEE	Göncüoğlu C,Çetinadam H,Demirkan K,Unal S "Sepsiste Statinlerin Rolü." , ss.369 - 377, 2021. 10.5578/flora.20219704
ISNAD	Göncüoğlu, Cansu vd. "Sepsiste Statinlerin Rolü". (2021), 369-377. https://doi.org/10.5578/flora.20219704

APA	Göncüoğlu C, Çetinadam H, Demirkan K, Unal S (2021). Sepsiste Statinlerin Rolü. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 26(3), 369 - 377. 10.5578/flora.20219704
Chicago	Göncüoğlu Cansu,Çetinadam Hafsa Nur,Demirkan Kutay,Unal Serhat Sepsiste Statinlerin Rolü. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 26, no.3 (2021): 369 - 377. 10.5578/flora.20219704
MLA	Göncüoğlu Cansu,Çetinadam Hafsa Nur,Demirkan Kutay,Unal Serhat Sepsiste Statinlerin Rolü. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, vol.26, no.3, 2021, ss.369 - 377. 10.5578/flora.20219704
AMA	Göncüoğlu C,Çetinadam H,Demirkan K,Unal S Sepsiste Statinlerin Rolü. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2021; 26(3): 369 - 377. 10.5578/flora.20219704
Vancouver	Göncüoğlu C,Çetinadam H,Demirkan K,Unal S Sepsiste Statinlerin Rolü. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2021; 26(3): 369 - 377. 10.5578/flora.20219704
IEEE	Göncüoğlu C,Çetinadam H,Demirkan K,Unal S "Sepsiste Statinlerin Rolü." Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 26, ss.369 - 377, 2021. 10.5578/flora.20219704
ISNAD	Göncüoğlu, Cansu vd. "Sepsiste Statinlerin Rolü". Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 26/3 (2021), 369-377. https://doi.org/10.5578/flora.20219704